Document is current
Any future updates will be listed below
-
Authors
van Lonkhuizen, Pearl J. C. https://orcid.org/0000-0002-7036-768X
Heemskerk, Anne-Wil
Slutter, Leanne
van Duijn, Erik https://orcid.org/0000-0003-2469-6252
de Bot, Susanne T. https://orcid.org/0000-0002-3512-2468
Chavannes, Niels H. https://orcid.org/0000-0002-8607-9199
Meijer, Eline https://orcid.org/0000-0001-7078-5067
,
Vegt, Niko
Chavannes, Niels
Heemskerk, Anne- Wil
de Bot, Susanne T.
van Lonkhuizen, Pearl J. C.
Vegt, Niko
Feleus, Stephanie
Arendts, Esther C
Putman, Amy
Landwehrmeyer, G. Bernhard
Mühlbäck, Alzbeta
Frank, Wiebke
Steck, Franziska
Klempíř, Jiří
Konvalinková, Romama
Bezuchová, Eva
Dolečková, Kristýna
Klempířová, Olga
Roth, Jan
Ulmanová, Olga
Squitieri, Ferdinando
Maffi, Sabrina
Scaricamazza, Eugenia
Migliore, Simone
Giorgio, Chiara
D’Alessio, Barbara
Casella, Melissa
Hoblyn, Jennifer
Thangaramanujam, Muthukumaran
Burke, Tom
O’Malley, Emer
McKenna, Stephen
McKenna, Ian
Thorpe, Jeanette
Coffey, Anna
Moldovan, Ramona
Foley, Peter
Kerr, Jacqueline
-
Funding
Funding for this research was provided by:
EU Joint Programme – Neurodegenerative Disease Research (01ED1903)
- License Information
-
More Information
Article History
Received: 16 February 2024
Accepted: 14 November 2024
First Online: 29 November 2024
Declarations
:
: This project was conducted in accordance with the Declaration of Helsinki and was cleared for ethics by the medical ethical research committee of Leiden Den Haag Delft in the Netherlands (file number: N20.013). All participants signed informed consent prior to participation in the interview. No relationship between researchers and participants was established prior to the start of this study.
: Not applicable.
: Susanne T. de Bot: Leiden University Medical Center receives grants from the European Huntington’s Disease Network (EHDN) and Cure HD Initiative (CHDI), participates in an EU Horizon 2020 project: Innovative Medicines Initiative (IMI) 2 (IDEA_FAST), and participates in clinical trials sponsored by PRILENIA, PTC Therapeutics, WAVE and VICO Therapeutics. The aforementioned sponsors had no role in the design, execution, interpretation, or writing of the current study. The other authors declare that they have no competing interests.
